cholangiocarcinoma

News

Loudspeaker used by a man, graphic art representation

'Dismal' survival demands change in bile duct cancer therapy

International cancer experts have called for big changes to bile duct cancer, which kills three-quarters of patients within a year of diagnosis.

News

NICE changes its mind on rare bile duct cancer drug from Inc...

Incyte's Pemazyre has become the first targeted therapy available for NHS patients with cholangiocarcinoma or bile duct cancer, after NICE concluded it provided value for money.

News

FDA approves Incyte's Pemazyre for rare bile duct cancer

The FDA has approved Incyte's Pemazyre (pemigatinib), the first targeted treatment for a rare cancer of the bile duct.

'Dismal' survival demands change in bile duct cancer therapy

NICE changes its mind on rare bile duct cancer drug from Inc...

FDA approves Incyte's Pemazyre for rare bile duct cancer

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Using AI-driven synthetic personas to take your insights fur...

Editor's Picks